Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Baudax Bio to Present at the H.C. Wainwright Annual Global Life Sciences Conference

MALVERN, Pa., May 18, 2022 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ:BXRX), a pharmaceutical company focused on innovative products for acute care settings, today announced that Gerri Henwood, the Company's President and Chief Executive Officer, will present at the H.C. Wainwright Annual Global Life Sciences Conference, taking place in Miami, Florida on Wednesday, May 25, 2022, at 1:30 p.m. Eastern Time.

A webcast of the presentation will be available on the "Events" page within the investors section of the Baudax Bio website at https://www.baudaxbio.com/news-and-investors. The webcast will be archived on the company's website for 90 days following the event.

About Baudax Bio

Baudax Bio is a pharmaceutical company focused on innovative products for acute care settings. ANJESO is the first and only 24-hour, intravenous (IV) COX-2 preferential non-steroidal anti-inflammatory (NSAID) for the management of moderate to severe pain. In addition to ANJESO, Baudax Bio has a pipeline of other innovative pharmaceutical assets including two novel neuromuscular blocking agents (NMBs) and a proprietary chemical reversal agent specific to these NMBs. For more information, please visit www.baudaxbio.com.

CONTACT:

Investor Relations Contact:

Argot Partners
Sam Martin / Kaela Ilami
(212) 600-1902
[email protected]

Media Contact:

Argot Partners
David Rosen
(212) 600-1902
[email protected]

Source: Baudax Bio, Inc.

Released May 18, 2022

Public link

Please use the above public link if you want to share this noodl on another website.